In the context of a rapidly growing AD population with no disease‐modifying therapeutics, targeting tau appears to be a plausible approach; the spatiotemporal pattern of tau pathology in AD is highly correlated with brain atrophy and observed cognitive decline (Giannopoulos, Chiu, & Praticò, 2018). This evidence concerns the gene MAPT and Brain atrophy.